Drug Buying Spree Still Bustling (Jan. 7 2015)Excerpts -- Big pharma will continue to search for prime assets to add to their pipelines, especially in immunotherapy, which harnesses the body’s immune system to fight the disease. “Oncology’s still the king of the hill and commands the broadest and deepest interest among buyers,” said JPMorgan’s Stute. January M&A Example --- Shire to Buy NPS Pharmaceuticals for $5.2 Billion (Jan 11 2015) Billion --- https://www.wsj.com/articles/shire-to-buy-nps-pharmaceuticals-for-5-2-billion-1420996764 --- Excerpt --- The market for rare-disease treatments is considered attractive, despite a small number of patients, because companies can command prices in the hundreds of thousands of dollars—as is the case with Gattex. Sales of so-called specialty drugs are forecast to reach $162 billion in 2018, up from $108 billion in 2013 and $81 billion in 2008, according to Credit Suisse. But is $5.2 billion enough??? -- PRESS RELEASE NPSP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches an Investigation of the Board of Directors of NPS Pharmaceuticals Inc. Regarding the Fairness of the Sale of the Company to Shire plc-- NPSP --- https://www.marketwatch.com/story/npsp-shareholder-alert-levi-korsinsky-llp-launches-an-investigation-of-the-board-of-directors-of-nps-pharmaceuticals-inc-regarding-the-fairness-of-the-sale-of-the-company-to-shire-plc---npsp-2015-01-13 --- Healthcare M&A in 2014 --- Healthcare was the most targeted industry globally in 2014 with $403.4bn, up from $296.8bn in 2013 and the highest full year on record. --- https://www.iichina.com/arfy/uploads/soft/141224/32320_0907352241.pdf